Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma

NCT04527549 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

NETWORK

Sponsor class

Stopped Slow accrual

Conditions

Clinical Stage IV Cutaneous Melanoma AJCC v8
Locally Advanced Melanoma
Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
Pathologic Stage IV Cutaneous Melanoma AJCC v8
Unresectable Melanoma

Interventions

DRUG: Dabrafenib mesylate
DRUG: Hydroxychloroquine
DRUG: Placebo Administration
DRUG: Trametinib dimethyl sulfoxide

Sponsor

ECOG-ACRIN Cancer Research Group

Collaborators

[object Object]